{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T17:37:03Z","timestamp":1792431423422,"version":"4.5.0"},"reference-count":136,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,1,31]],"date-time":"2022-01-31T00:00:00Z","timestamp":1643587200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Metabolism of tryptophan (Trp), an essential amino acid, represent a major metabolic pathway that both promotes tumor cell intrinsic malignant properties as well as restricts antitumour immunity, thus emerging as a drug development target for cancer immunotherapy. Three cytosolic enzymes, namely indoleamine 2,3-dioxygenase 1 (IDO1), IDO2 and tryptophan 2,3-dioxygenase (TDO2), catalyzes the first-rate limiting step of the degradation of Trp to kynurenine (Kyn) and modulates immunity toward immunosuppression mainly through the aryl hydrocarbon receptor (AhR) activation in numerous types of cancer. By restoring antitumor immune responses and synergizing with other immunotherapies, the encouraging preclinical data of IDO1 inhibitors has dramatically failed to translate into clinical success when combined with immune checkpoints inhibitors, reigniting the debate of combinatorial approach. In this review, we i) provide comprehensive evidences on immunomodulatory role of the Trp catabolism metabolites that highlight this pathway as relevant target in immuno-oncology, ii)ii) discuss underwhelming results from clinical trials investigating efficacy of IDO1 inhibitors and underlying mechanisms that might have contributed to this failure, and finally, iii) discuss the current state-of-art surrounding alternative approaches of innovative antitumor immunotherapies that target molecules of Trp catabolism as well as challenges and perspectives in the era of immunotherapy.<\/jats:p>","DOI":"10.3389\/fimmu.2022.807271","type":"journal-article","created":{"date-parts":[[2022,1,31]],"date-time":"2022-01-31T06:25:09Z","timestamp":1643610309000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":129,"title":["Targeting Tryptophan Catabolism in Cancer Immunotherapy Era: Challenges and Perspectives"],"prefix":"10.3389","volume":"13","author":[{"given":"Florent","family":"Peyraud","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Philippe","family":"Guegan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Bodet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Cousin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alban","family":"Bessede","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Italiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,1,31]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1203486","article-title":"Cancer Immunoediting: Integrating Immunity\u2019s Roles in Cancer Suppression and Promotion","volume":"331","author":"Schreiber","year":"2011","journal-title":"Science"},{"key":"B2","doi-asserted-by":"publisher","first-page":"3801","DOI":"10.1038\/s41467-020-17670-y","article-title":"A Decade of Immune-Checkpoint Inhibitors in Cancer Therapy","volume":"11","author":"Robert","year":"2020","journal-title":"Nat Commun"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.01.017","article-title":"Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy","volume":"168","author":"Sharma","year":"2017","journal-title":"Cell"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065X.2006.00442.x","article-title":"Immune Resistance Orchestrated by the Tumor Microenvironment","volume":"213","author":"Gajewski","year":"2006","journal-title":"Immunol Rev"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxw014","article-title":"Mechanisms of Tumor Escape in the Context of the T-Cell-Inflamed and the non-T-Cell-Inflamed Tumor Microenvironment","volume":"28","author":"Spranger","year":"2016","journal-title":"Int Immunol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"xii18","DOI":"10.1093\/annonc\/mdx238","article-title":"Mechanisms Regulating T-Cell Infiltration and Activity in Solid Tumors","volume":"28","author":"Lanitis","year":"2017","journal-title":"Ann Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2017.11.007","article-title":"Targeting the IDO1\/TDO2\u2013KYN\u2013AhR Pathway for Cancer Immunotherapy \u2013 Challenges and Opportunities","volume":"39","author":"Cheong","year":"2018","journal-title":"Trends Pharmacol Sci"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1126\/science.281.5380.1191","article-title":"Prevention of Allogeneic Fetal Rejection by Tryptophan Catabolism","volume":"281","author":"Munn","year":"1998","journal-title":"Science"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1172\/JCI21583","article-title":"Expression of Indoleamine 2,3-Dioxygenase by Plasmacytoid Dendritic Cells in Tumor-Draining Lymph Nodes","volume":"114","author":"Munn","year":"2004","journal-title":"J Clin Invest"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-1966","article-title":"Prognostic Value of Indoleamine 2,3-Dioxygenase Expression in Colorectal Cancer: Effect on Tumor-Infiltrating T Cells","volume":"12","author":"Brandacher","year":"2006","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"B11","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/nature10491","article-title":"An Endogenous Tumour-Promoting Ligand of the Human Aryl Hydrocarbon Receptor","volume":"478","author":"Opitz","year":"2011","journal-title":"Nature"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2012.10.001","article-title":"Indoleamine 2,3 Dioxygenase and Metabolic Control of Immune Responses","volume":"34","author":"Munn","year":"2013","journal-title":"Trends Immunol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/nature13323","article-title":"Aryl Hydrocarbon Receptor Control of a Disease Tolerance Defence Pathway","volume":"511","author":"Bessede","year":"2014","journal-title":"Nature"},{"key":"B14","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.immuni.2017.12.012","article-title":"Regulation of the Immune Response by the Aryl Hydrocarbon Receptor","volume":"48","author":"Guti\u00e9rrez-V\u00e1zquez","year":"2018","journal-title":"Immunity"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-014-1549-4","article-title":"Indoleamine 2,3-Dioxygenase Pathways of Pathogenic Inflammation and Immune Escape in Cancer","volume":"63","author":"Prendergast","year":"2014","journal-title":"Cancer Immunol Immunother CII"},{"key":"B16","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.it.2016.01.002","article-title":"IDO in the Tumor Microenvironment: Inflammation, Counter-Regulation, and Tolerance","volume":"37","author":"Munn","year":"2016","journal-title":"Trends Immunol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1186\/2051-1426-2-3","article-title":"Mechanism of Tumor Rejection With Doublets of CTLA-4, PD-1\/PD-L1, or IDO Blockade Involves Restored IL-2 Production and Proliferation of CD8(+) T Cells Directly Within the Tumor Microenvironment","volume":"2","author":"Spranger","year":"2014","journal-title":"J Immunother Cancer"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1177\/1178646917691938","article-title":"Kynurenine Pathway of Tryptophan Metabolism: Regulatory and Functional Aspects","volume":"10","author":"Badawy","year":"2017","journal-title":"Int J Tryptophan Res IJTR"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.679953","article-title":"Current Challenges for IDO2 as Target in Cancer Immunotherapy","volume":"12","author":"Mondanelli","year":"2021","journal-title":"Front Immunol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/ni.2077","article-title":"Indoleamine 2,3-Dioxygenase is a Signaling Protein in Long-Term Tolerance by Dendritic Cells","volume":"12","author":"Pallotta","year":"2011","journal-title":"Nat Immunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/ni.2088","article-title":"IDO: More Than an Enzyme","volume":"12","author":"Chen","year":"2011","journal-title":"Nat Immunol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.271.32.19140","article-title":"Importance of the Two Interferon-Stimulated Response Element (ISRE) Sequences in the Regulation of the Human Indoleamine 2,3-Dioxygenase Gene *","volume":"271","author":"Konan","year":"1996","journal-title":"J Biol Chem"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.1637","article-title":"Constitutive IDO Expression in Human Cancer is Sustained by an Autocrine Signaling Loop Involving IL-6, STAT3 and the AHR","volume":"5","author":"Litzenburger","year":"2014","journal-title":"Oncotarget"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1111\/jnc.13503","article-title":"Tryptophan-2,3-Dioxygenase is Regulated by Prostaglandin E2 in Malignant Glioma via a Positive Signaling Loop Involving Prostaglandin E Receptor-4","volume":"136","author":"Ochs","year":"2016","journal-title":"J Neurochem"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-09-246124","article-title":"Selective Inhibition of IDO1 Effectively Regulates Mediators of Antitumor Immunity","volume":"115","author":"Liu","year":"2010","journal-title":"Blood"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1113873109","article-title":"Reversal of Tumoral Immune Resistance by Inhibition of Tryptophan 2,3-Dioxygenase","volume":"109","author":"Pilotte","year":"2012","journal-title":"Proc Natl Acad Sci"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2014.1003012","article-title":"Expression Profile of the Human IDO1 Protein, a Cancer Drug Target Involved in Tumoral Immune Resistance","volume":"4","author":"Vigneron","year":"2015","journal-title":"OncoImmunology"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-14-0137","article-title":"Extensive Profiling of the Expression of the Indoleamine 2,3-Dioxygenase 1 Protein in Normal and Tumoral Human Tissues","volume":"3","author":"Th\u00e9ate","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2017.01.011","article-title":"The Rationale of Indoleamine 2,3-Dioxygenase Inhibition for Cancer Therapy","volume":"76","author":"Brochez","year":"2017","journal-title":"Eur J Cancer Oxf Engl 1990"},{"key":"B31","doi-asserted-by":"publisher","first-page":"4447","DOI":"10.1038\/s41467-021-24785-3","article-title":"3-Hydroxy-L-Kynurenamine is an Immunomodulatory Biogenic Amine","volume":"12","author":"Clement","year":"2021","journal-title":"Nat Commun"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1084\/jem.189.9.1363","article-title":"Inhibition of T Cell Proliferation by Macrophage Tryptophan Catabolism","volume":"189","author":"Munn","year":"1999","journal-title":"J\u00a0Exp Med"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2567.2002.01526.x","article-title":"Tryptophan Deprivation Sensitizes Activated T Cells to Apoptosis Prior to Cell Division","volume":"107","author":"Lee","year":"2002","journal-title":"Immunology"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/sj.cdd.4401073","article-title":"T Cell Apoptosis by Tryptophan Catabolism","volume":"9","author":"Fallarino","year":"2002","journal-title":"Cell Death Differ"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2005.03.013","article-title":"GCN2 Kinase in T Cells Mediates Proliferative Arrest and Anergy Induction in Response to Indoleamine 2,3-Dioxygenase","volume":"22","author":"Munn","year":"2005","journal-title":"Immunity"},{"key":"B36","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1111\/imm.12502","article-title":"Indoleamine 2,3-Dioxygenase Depletes Tryptophan, Activates General Control non-Derepressible 2 Kinase and Down-Regulates Key Enzymes Involved in Fatty Acid Synthesis in Primary Human CD4+ T Cells","volume":"146","author":"Eleftheriadis","year":"2015","journal-title":"Immunology"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.176.11.6752","article-title":"The Combined Effects of Tryptophan Starvation and Tryptophan Catabolites Down-Regulate T Cell Receptor Zeta-Chain and Induce a Regulatory Phenotype in Naive T Cells","volume":"176","author":"Fallarino","year":"2006","journal-title":"J Immunol Baltim Md 1950"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2016.1240858","article-title":"The Stress Kinase GCN2 Does Not Mediate Suppression of Antitumor T Cell Responses by Tryptophan Catabolism in Experimental Melanomas","volume":"5","author":"Sonner","year":"2016","journal-title":"OncoImmunology"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamcr.2014.04.006","article-title":"Keeping the Eif2 Alpha Kinase Gcn2 in Check","volume":"1843","author":"Castilho","year":"2014","journal-title":"Biochim Biophys Acta"},{"key":"B40","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1093\/toxsci\/kfq024","article-title":"Kynurenic Acid Is a Potent Endogenous Aryl Hydrocarbon Receptor Ligand That Synergistically Induces Interleukin-6 in the Presence of Inflammatory Signaling","volume":"115","author":"DiNatale","year":"2010","journal-title":"Toxicol Sci"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1014465107","article-title":"Aryl Hydrocarbon Receptor Negatively Regulates Dendritic Cell Immunogenicity via a Kynurenine-Dependent Mechanism","volume":"107","author":"Nguyen","year":"2010","journal-title":"Proc Natl Acad Sci"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0903670","article-title":"An Interaction Between Kynurenine and the Aryl Hydrocarbon Receptor can Generate Regulatory T Cells","volume":"185","author":"Mezrich","year":"2010","journal-title":"J Immunol Baltim Md 1950"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-019-0125-8","article-title":"The Aryl Hydrocarbon Receptor: An Environmental Sensor Integrating Immune Responses in Health and Disease","volume":"19","author":"Rothhammer","year":"2019","journal-title":"Nat Rev Immunol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M117.812974","article-title":"The Crystal Structure of the AhRR\u2013ARNT Heterodimer Reveals the Structural Basis of the Repression of AhR-Mediated Transcription","volume":"292","author":"Sakurai","year":"2017","journal-title":"J Biol Chem"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.00630-16","article-title":"Poellinger L. A Molecular Mechanism To Switch the Aryl Hydrocarbon Receptor From a Transcription Factor to an E3 Ubiquitin Ligase","volume":"37","author":"Luecke-Johansson","year":"2017","journal-title":"Mol Cell Biol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M113.505578","article-title":"Cross-Talk Between Aryl Hydrocarbon Receptor and the Inflammatory Response: A Role for Nuclear Factor-\u03bab","volume":"289","author":"Vogel","year":"2014","journal-title":"J Biol Chem"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20090560","article-title":"Aryl Hydrocarbon Receptor in Combination With Stat1 Regulates LPS-Induced Inflammatory Responses","volume":"206","author":"Kimura","year":"2009","journal-title":"J Exp Med"},{"key":"B48","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1074\/jbc.RA117.000631","article-title":"Trace Derivatives of Kynurenine Potently Activate the Aryl Hydrocarbon Receptor (AHR)","volume":"293","author":"Seok","year":"2018","journal-title":"J Biol Chem"},{"key":"B49","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.ccell.2018.02.005","article-title":"Tumor-Repopulating Cells Induce PD-1 Expression in CD8+ T Cells by Transferring Kynurenine and AhR Activation","volume":"33","author":"Liu","year":"2018","journal-title":"Cancer Cell"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-18-0362","article-title":"Richer JK. A Role for Tryptophan-2,3-Dioxygenase in CD8 T-Cell Suppression and Evidence of Tryptophan Catabolism in Breast Cancer Patient Plasma","volume":"17","author":"Greene","year":"2019","journal-title":"Mol Cancer Res MCR"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1009201107","article-title":"An Endogenous Aryl Hydrocarbon Receptor Ligand Acts on Dendritic Cells and T Cells to Suppress Experimental Autoimmune Encephalomyelitis","volume":"107","author":"Quintana","year":"2010","journal-title":"Proc Natl Acad Sci"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1300497","article-title":"The Aryl Hydrocarbon Receptor Promotes IL-10 Production by NK Cells","volume":"192","author":"Wagage","year":"2014","journal-title":"J Immunol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1111\/cei.12352","article-title":"Activation of the Aryl Hydrocarbon Receptor Affects Activation and Function of Human Monocyte-Derived Dendritic Cells","volume":"177","author":"Wang","year":"2014","journal-title":"Clin Exp Immunol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1038\/s41593-019-0370-y","article-title":"Control of Tumor-Associated Macrophages and T Cells in Glioblastoma via AHR and CD39","volume":"22","author":"Takenaka","year":"2019","journal-title":"Nat Neurosci"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1038\/ni.1912","article-title":"The Aryl Hydrocarbon Receptor Interacts With C-Maf to Promote the Differentiation of Type 1 Regulatory T Cells Induced by IL-27","volume":"11","author":"Apetoh","year":"2010","journal-title":"Nat Immunol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1038\/cr.2016.151","article-title":"Regulatory T Cells in Cancer Immunotherapy","volume":"27","author":"Tanaka","year":"2017","journal-title":"Cell Res"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2016.01.004","article-title":"The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment","volume":"37","author":"Kumar","year":"2016","journal-title":"Trends Immunol"},{"key":"B58","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s13045-017-0430-2","article-title":"Tumor-Associated Macrophages: From Basic Research to Clinical Application","volume":"10","author":"Yang","year":"2017","journal-title":"J Hematol OncolJ Hematol Oncol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200636690","article-title":"Cell-Autonomous Control of Interferon Type I Expression by Indoleamine 2,3-Dioxygenase in Regulatory CD19+ Dendritic Cells","volume":"37","author":"Manlapat","year":"2007","journal-title":"Eur J Immunol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1038\/ni.3422","article-title":"Constitutive Aryl Hydrocarbon Receptor Signaling Constrains Type I Interferon\u2013Mediated Antiviral Innate Defense","volume":"17","author":"Yamada","year":"2016","journal-title":"Nat Immunol"},{"key":"B61","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/nature06880","article-title":"Control of T Reg and T H 17 Cell Differentiation by the Aryl Hydrocarbon Receptor","volume":"453","author":"Quintana","year":"2008","journal-title":"Nature"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1120611109","article-title":"Nanoparticle-Mediated Codelivery of Myelin Antigen and a Tolerogenic Small Molecule Suppresses Experimental Autoimmune Encephalomyelitis","volume":"109","author":"Yeste","year":"2012","journal-title":"Proc Natl Acad Sci"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13112667","article-title":"Not Only Immune Escape\u2014The Confusing Role of the TRP Metabolic Pathway in Carcinogenesis","volume":"13","author":"Kwiatkowska","year":"2021","journal-title":"Cancers"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1302856110","article-title":"Modulation of Natural Killer Cell Antitumor Activity by the Aryl Hydrocarbon Receptor","volume":"110","author":"Shin","year":"2013","journal-title":"Proc Natl Acad Sci"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.14800\/ics.1404","article-title":"Aryl Hydrocarbon Receptor Activation and IL-2 Have Synergistic Effects That Enhance Human Natural Killer Cell Cytotoxicity","volume":"196","author":"Li","year":"2016","journal-title":"J Immunol"},{"key":"B66","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.immuni.2017.08.016","article-title":"Aryl Hydrocarbon Receptor Controls Monocyte Differentiation Into Dendritic Cells Versus Macrophages","volume":"47","author":"Goudot","year":"2017","journal-title":"Immunity"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.4161\/2162402X.2014.982382","article-title":"Characterization of the In Vivo Immune Network of IDO, Tryptophan Metabolism, PD-L1, and CTLA-4 in Circulating Immune Cells in Melanoma","volume":"4","author":"Chevolet","year":"2015","journal-title":"OncoImmunology"},{"key":"B68","doi-asserted-by":"publisher","first-page":"200ra116","DOI":"10.1126\/scitranslmed.3006504","article-title":"Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells","volume":"5","author":"Spranger","year":"2013","journal-title":"Sci Transl Med"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1038\/ni1003","article-title":"Modulation of Tryptophan Catabolism by Regulatory T Cells","volume":"4","author":"Fallarino","year":"2003","journal-title":"Nat Immunol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2016.00009","article-title":"Tolerogenic IDO(+) Dendritic Cells Are Induced by PD-1-Expressing Mast Cells","volume":"7","author":"Rodrigues","year":"2016","journal-title":"Front Immunol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.1500845","article-title":"The PTEN Pathway in Tregs is a Critical Driver of the Suppressive Tumor Microenvironment","volume":"1","author":"Sharma","year":"2015","journal-title":"Sci Adv"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.678999","article-title":"IDO1 Expression in Ovarian Cancer Induces PD-1 in T Cells via Aryl Hydrocarbon Receptor Activation","volume":"12","author":"Amobi-McCloud","year":"2021","journal-title":"Front Immunol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20130066","article-title":"Indoleamine 2,3-Dioxygenase is a Critical Resistance Mechanism in Antitumor T Cell Immunotherapy Targeting CTLA-4","volume":"210","author":"Holmgaard","year":"2013","journal-title":"J Exp Med"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-0514","article-title":"Durable Therapeutic Efficacy Utilizing Combinatorial Blockade Against IDO, CTLA-4, and PD-L1 in Mice With Brain Tumors","volume":"20","author":"Wainwright","year":"2014","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-2882","article-title":"Reimagining IDO Pathway Inhibition in Cancer Immunotherapy via Downstream Focus on the Tryptophan\u2013Kynurenine\u2013Aryl Hydrocarbon Axis","volume":"25","author":"Labadie","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-12-0014","article-title":"IDO is a Nodal Pathogenic Driver of Lung Cancer and Metastasis Development","volume":"2","author":"Smith","year":"2012","journal-title":"Cancer Discovery"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1038\/nm934","article-title":"Evidence for a Tumoral Immune Resistance Mechanism Based on Tryptophan Degradation by Indoleamine 2,3-Dioxygenase","volume":"9","author":"Uyttenhove","year":"2003","journal-title":"Nat Med"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-1331","article-title":"Indoleamine 2,3-Dioxygenase Expression in Human Cancers: Clinical and Immunologic Perspectives","volume":"17","author":"Godin-Ethier","year":"2011","journal-title":"Clin Cancer Res"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1021\/acsmedchemlett.6b00391","article-title":"INCB24360 (Epacadostat), a Highly Potent and Selective Indoleamine-2,3-Dioxygenase 1 (IDO1) Inhibitor for Immuno-Oncology","volume":"8","author":"Yue","year":"2017","journal-title":"ACS Med Chem Lett"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.9326","article-title":"The IDO1 Selective Inhibitor Epacadostat Enhances Dendritic Cell Immunogenicity and Lytic Ability of Tumor Antigen-Specific T Cells","volume":"7","author":"Jochems","year":"2016","journal-title":"Oncotarget"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-09-0628","article-title":"Hydroxyamidine Inhibitors of Indoleamine-2,3-Dioxygenase Potently Suppress Systemic Tryptophan Catabolism and the Growth of IDO-Expressing Tumors","volume":"9","author":"Koblish","year":"2010","journal-title":"Mol Cancer Ther"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2017-572","article-title":"Abstract 572: Inhibition of IDO1 With Epacadostat Enhances Anti-Tumor Efficacy of PD-1 Blockade in a Syngeneic Glioblastoma (GBM) Model","volume":"77","author":"Reardon","year":"2017","journal-title":"Cancer Res"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-2272","article-title":"First-In-Human Phase I Study of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase-1 Epacadostat (INCB024360) in Patients With Advanced Solid Malignancies","volume":"23","author":"Beatty","year":"2017","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V124.21.4653.4653","article-title":"A Phase II Study to Determine the Safety and Efficacy of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase (IDO) Enzyme INCB024360 in Patients With Myelodysplastic Syndromes","volume":"124","author":"Komrokji","year":"2014","journal-title":"Blood"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2017.07.005","article-title":"A Randomised, Open-Label, Phase 2 Study of the IDO1 Inhibitor Epacadostat (INCB024360) Versus Tamoxifen as Therapy for Biochemically Recurrent (CA-125 Relapse)\u2013Only Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma, or Fallopian Tube Cancer","volume":"146","author":"Kristeleit","year":"2017","journal-title":"Gynecol Oncol"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30274-8","article-title":"Epacadostat Plus Pembrolizumab Versus Placebo Plus Pembrolizumab in Patients With Unresectable or Metastatic Melanoma (ECHO-301\/KEYNOTE-252): A Phase 3, Randomised, Double-Blind Study","volume":"20","author":"Long","year":"2019","journal-title":"Lancet Oncol"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2013-491","article-title":"Abstract 491: NLG919, a Novel Indoleamine-2,3-Dioxygenase (IDO)-Pathway Inhibitor Drug Candidate for Cancer Therapy","volume":"73","author":"Mautino","year":"2013","journal-title":"Cancer Res"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2014-5023","article-title":"Abstract 5023: Synergistic Antitumor Effects of Combinatorial Immune Checkpoint Inhibition With Anti-PD-1\/PD-L Antibodies and the IDO Pathway Inhibitors NLG-919 and Indoximod in the Context of Active Immunotherapy","volume":"74","author":"Mautino","year":"2014","journal-title":"Cancer Res"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1186\/2051-1426-3-S2-P303","article-title":"Improved Anti-Tumor Immunity and Efficacy Upon Combination of the IDO1 Inhibitor GDC-0919 With Anti-PD-L1 Blockade Versus Anti-PD-L1 Alone in Preclinical Tumor Models","volume":"3","author":"Spahn","year":"2015","journal-title":"J Immunother Cancer"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-2740","article-title":"Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered With PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors","volume":"25","author":"Jung","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2017-4964","article-title":"Abstract 4964: Structure, In Vitro Biology and In Vivo Pharmacodynamic Characterization of a Novel Clinical IDO1 Inhibitor","volume":"77","author":"Hunt","year":"2017","journal-title":"Cancer Res"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2017-CT116","article-title":"Abstract CT116: BMS-986205, an Optimized Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor, is Well Tolerated With Potent Pharmacodynamic (PD) Activity, Alone and in Combination With Nivolumab (Nivo) in Advanced Cancers in a Phase 1\/2a Trial","volume":"77","author":"Siu","year":"2017","journal-title":"Cancer Res"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-020-00950-1","article-title":"A Phase 1 Study of PF-06840003, an Oral Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor in Patients With Recurrent Malignant Glioma","volume":"38","author":"Reardon","year":"2020","journal-title":"Invest New Drugs"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2016-4863","article-title":"Abstract 4863: PF-06840003: A Highly Selective IDO-1 Inhibitor That Shows Good In Vivo Efficacy in Combination With Immune Checkpoint Inhibitors","volume":"76","author":"Tumang","year":"2016","journal-title":"Cancer Res"},{"key":"B95","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1158\/0008-5472.CAN-06-2925","article-title":"Inhibition of Indoleamine 2,3-Dioxygenase in Dendritic Cells by Stereoisomers of 1-Methyl-Tryptophan Correlates With Antitumor Responses","volume":"67","author":"Hou","year":"2007","journal-title":"Cancer Res"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.4161\/onci.21716","article-title":"IDO Inhibits a Tryptophan Sufficiency Signal That Stimulates mTOR: A Novel IDO Effector Pathway Targeted by D-1-Methyl-Tryptophan","volume":"1","author":"Metz","year":"2012","journal-title":"OncoImmunology"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.27646","article-title":"Indoximod Opposes the Immunosuppressive Effects Mediated by IDO and TDO via Modulation of AhR Function and Activation of Mtorc1","volume":"11","author":"Brincks","year":"2020","journal-title":"Oncotarget"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00370","article-title":"Indoximod: An Immunometabolic Adjuvant That Empowers T Cell Activity in Cancer","volume":"8","author":"Fox","year":"2018","journal-title":"Front Oncol"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-NB2017-056","article-title":"Indoximod Combo Triggers Responses in Melanoma","volume":"7","author":"Colwell","year":"2017","journal-title":"Cancer Discov"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-002057","article-title":"Phase II Trial of the IDO Pathway Inhibitor Indoximod Plus Pembrolizumab for the Treatment of Patients With Advanced Melanoma","volume":"9","author":"Zakharia","year":"2021","journal-title":"J\u00a0Immunother Cancer"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2020.112373","article-title":"Discovery of Indoximod Prodrugs and Characterization of Clinical Candidate NLG802","volume":"198","author":"Kumar","year":"2020","journal-title":"Eur J Med Chem"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0000000000000368","article-title":"A Phase I Study of an IDO-1 Inhibitor (LY3381916) as Monotherapy and in Combination With an Anti-PD-L1 Antibody (LY3300054) in Patients With Advanced Cancer","volume":"144","author":"Kotecki","year":"2021","journal-title":"J Immunother Hagerstown Md 1997"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01544-x","article-title":"A Phase 1\/2 Trial of an Immune-Modulatory Vaccine Against IDO\/PD-L1 in Combination With Nivolumab in Metastatic Melanoma","volume":"27","author":"Kjeldsen","year":"2021","journal-title":"Nat Med"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2018-LB-128","article-title":"Abstract LB-128: The Aryl Hydrocarbon Receptor as Driver of Cancer Immunity","volume":"78","author":"Sherr","year":"2018","journal-title":"Cancer Res"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2018-4719","article-title":"Abstract 4719: Small-Molecule Antagonists of the Aryl Hydrocarbon Receptor (AhR) Promote Activation of Human PBMCs In Vitro and Demonstrate Significant Impact on Tumor Growth and Immune Modulation In Vivo","volume":"78","author":"Joseph","year":"2018","journal-title":"Cancer Res"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2017-5570","article-title":"Abstract 5570: A Novel Approach to Targeting the IDO\/TDO Pathway Through Degradation of the Immunosuppressive Metabolite Kynurenine","volume":"77","author":"Zhang","year":"2017","journal-title":"Cancer Res"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2017-5571","article-title":"Abstract 5571: Immune-Checkpoint Inhibition via Enzyme-Mediated Degradation of Kynurenine","volume":"77","author":"Triplett","year":"2017","journal-title":"Cancer Res"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2015-LB-226","article-title":"Abstract LB-226: Depletion of Kynurenine Using an Engineered Therapeutic Enzyme Potently Inhibits Cancer Immune Checkpoints Both as a Monotherapy and in Combination With Anti-PD-1","volume":"75","author":"Stone","year":"2015","journal-title":"Cancer Res"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.4180","article-title":"Reversal of Indoleamine 2,3-Dioxygenase\u2013Mediated Cancer Immune Suppression by Systemic Kynurenine Depletion With a Therapeutic Enzyme","volume":"36","author":"Triplett","year":"2018","journal-title":"Nat Biotechnol"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3846","article-title":"Aryl Hydrocarbon Receptor Ligands In Cancer: Friend and Foe","volume":"14","author":"Murray","year":"2014","journal-title":"Nat Rev Cancer"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-12-0569","article-title":"Tryptophan Catabolism in Cancer: Beyond IDO and Tryptophan Depletion","volume":"72","author":"Platten","year":"2012","journal-title":"Cancer Res"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22094644","article-title":"Tryptophan Metabolites at the Crossroad of Immune-Cell Interaction via the Aryl Hydrocarbon Receptor: Implications for Tumor Immunotherapy","volume":"22","author":"Gargaro","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.01183-13","article-title":"Ligand Promiscuity of Aryl Hydrocarbon Receptor Agonists and Antagonists Revealed by Site-Directed Mutagenesis","volume":"34","author":"Soshilov","year":"2014","journal-title":"Mol Cell Biol"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1021\/tx7001965","article-title":"The Search for Endogenous Activators of the Aryl Hydrocarbon Receptor","volume":"21","author":"Nguyen","year":"2008","journal-title":"Chem Res Toxicol"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2013.362","article-title":"The New Aryl Hydrocarbon Receptor Antagonist E\/Z-2-Benzylindene-5,6-Dimethoxy-3,3-Dimethylindan-1-One Protects Against UVB-Induced Signal Transduction","volume":"134","author":"Tigges","year":"2014","journal-title":"J Invest Dermatol"},{"key":"B116","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1124\/mol.114.093369","article-title":"In Silico Identification of an Aryl Hydrocarbon Receptor Antagonist With Biological Activity In Vitro and In Vivo","volume":"86","author":"Parks","year":"2014","journal-title":"Mol Pharmacol"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2019-1210","article-title":"Abstract 1210: Targeting the IDO1-Kynurenine-AhR Pathway for Cancer Immunotherapy","volume":"79","author":"Pinto","year":"2019","journal-title":"Cancer Res"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2019-1288","article-title":"Abstract 1288: Blocking Tumor-Associated Immune Suppression With BAY-218, a Novel, Selective Aryl Hydrocarbon Receptor (AhR) Inhibitor","volume":"79","author":"Gutcher","year":"2019","journal-title":"Cancer Res"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2019-4454","article-title":"Abstract 4454: Identification of BAY-218, a Potent and Selective Small-Molecule AhR Inhibitor, as a New Modality to Counteract Tumor Immunosuppression","volume":"79","author":"Schmees","year":"2019","journal-title":"Cancer Res"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1210\/me.2009-0346","article-title":"Activation of the Aryl-Hydrocarbon Receptor Inhibits Invasive and Metastatic Features of Human Breast Cancer Cells and Promotes Breast Cancer Cell Differentiation","volume":"24","author":"Hall","year":"2010","journal-title":"Mol Endocrinol"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0013831","article-title":"Breast Cancer Stem-Like Cells Are Inhibited by a Non-Toxic Aryl Hydrocarbon Receptor Agonist","volume":"5","author":"Prud\u2019homme","year":"2010","journal-title":"PloS One"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1093\/toxsci\/kfr247","article-title":"Activation of the Aryl Hydrocarbon Receptor by TCDD Inhibits Mammary Tumor Metastasis in a Syngeneic Mouse Model of Breast Cancer","volume":"124","author":"Wang","year":"2011","journal-title":"Toxicol Sci"},{"key":"B123","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.taap.2017.03.012","article-title":"Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors Activate the Aryl Hydrocarbon Receptor","volume":"323","author":"Moyer","year":"2017","journal-title":"Toxicol Appl Pharmacol"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-0420","article-title":"Molecular Pathways: Targeting IDO1 and Other Tryptophan Dioxygenases for Cancer Immunotherapy","volume":"21","author":"Zhai","year":"2015","journal-title":"Clin Cancer Res"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1038\/cmi.2017.143","article-title":"IDO1 in Cancer: A Gemini of Immune Checkpoints","volume":"15","author":"Zhai","year":"2018","journal-title":"Cell Mol Immunol"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.18632\/aging.203492","article-title":"Challenges in Targeting the Tryptophan Metabolism Incancer Immunotherapy","volume":"13","author":"Schollbach","year":"2021","journal-title":"Aging"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1021\/acsmedchemlett.6b00458","article-title":"Targeting the Inhibition of Tryptophan 2,3-Dioxygenase (TDO-2) for Cancer Treatment","volume":"8","author":"Abdel-Magid","year":"2017","journal-title":"ACS Med Chem Lett"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbagen.2016.07.002","article-title":"Tryptophan 2,3-Dioxygenase and Indoleamine 2,3-Dioxygenase 1 Make Separate, Tissue-Specific Contributions to Basal and Inflammation-Induced Kynurenine Pathway Metabolism in Mice","volume":"1860","author":"Larkin","year":"2016","journal-title":"Biochim Biophys Acta"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2016-LB-085","article-title":"Abstract LB-085: RG70099: A Novel, Highly Potent Dual IDO1\/TDO Inhibitor to Reverse Metabolic Suppression of Immune Cells in the Tumor Micro-Environment","volume":"76","author":"Gyulveszi","year":"2016","journal-title":"Cancer Res"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2018-1701","article-title":"Abstract 1701: EPL-1410, a Novel Fused Heterocycle Based Orally Active Dual Inhibitor of IDO1\/TDO2, as a Potential Immune-Oncology Therapeutic","volume":"78","author":"Gullapalli","year":"2018","journal-title":"Cancer Res"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.e14228","article-title":"A Novel Dual Inhibitor of IDO and TDO, CMG017, Potently Suppresses the Kynurenine Pathway and Overcomes Resistance to Immune Checkpoint Inhibitors","volume":"37","author":"Kim","year":"2019","journal-title":"J Clin Oncol"},{"key":"B132","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/nrmicro.2018.12","article-title":"Microbiome: Gut Microbiota Sways Response to Cancer Immunotherapy","volume":"16","author":"York","year":"2018","journal-title":"Nat Rev Microbiol"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1126\/science.aan3706","article-title":"Gut Microbiome Influences Efficacy of PD-1-Based Immunotherapy Against Epithelial Tumors","volume":"359","author":"Routy","year":"2018","journal-title":"Science"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2018.00013","article-title":"Impact of the Gut Microbiota on Intestinal Immunity Mediated by Tryptophan Metabolism","volume":"8","author":"Gao","year":"2018","journal-title":"Front Cell Infect Microbiol"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002616","article-title":"Off-Tumor IDO1 Target Engagements Determine the Cancer-Immune Set Point and Predict the Immunotherapeutic Efficacy","volume":"9","author":"Xie","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B136","doi-asserted-by":"publisher","first-page":"4346","DOI":"10.1038\/s41467-019-12361-9","article-title":"Metabolomic Adaptations and Correlates of Survival to Immune Checkpoint Blockade","volume":"10","author":"Li","year":"2019","journal-title":"Nat Commun"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01243","article-title":"Tryptophan Catabolism as Immune Mechanism of Primary Resistance\u00a0to\u00a0Anti-PD-1","volume":"11","author":"Botticelli","year":"2020","journal-title":"Front Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.807271\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,31]],"date-time":"2022-01-31T06:25:12Z","timestamp":1643610312000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.807271\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,31]]},"references-count":136,"alternative-id":["10.3389\/fimmu.2022.807271"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.807271","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,31]]},"article-number":"807271"}}